OpenEvidence Stock: Public Trading Status & Investor Guide
If you are searching for OpenEvidence stock, the most important thing to know is that OpenEvidence is not currently a publicly traded company. It does not have a public stock ticker on the NYSE or Nasdaq, and ordinary investors cannot buy its shares through a standard brokerage account.
OpenEvidence is a privately held healthcare artificial-intelligence company that provides an AI-powered medical information platform for clinicians. The company has attracted substantial venture-capital backing and reached multibillion-dollar private-market valuations, which explains the growing interest in a potential OpenEvidence IPO and OpenEvidence stock.
As of October 2026, however, there is no publicly traded OpenEvidence stock.
Quick Answer: Can You Buy OpenEvidence Stocks?
No, not through a regular stock brokerage.
OpenEvidence remains privately held, meaning its shares are not listed on a public stock exchange and there is no official public-market ticker symbol.
Private-market platforms may facilitate transactions involving OpenEvidence shares for eligible investors, but these transactions are fundamentally different from buying a listed stock. Access can be restricted, shares can be illiquid, and transaction prices may differ substantially from one another.
Nasdaq Private Market, for example, states that OpenEvidence stock does not trade on public exchanges and that its private-market transactions are currently limited to accredited entities and institutional investors. NNasdaq Private Market
| OpenEvidence Stock Question | Current Status |
|---|---|
| Is OpenEvidence publicly traded? | No |
| OpenEvidence ticker symbol | None |
| Listed on Nasdaq? | No |
| Listed on NYSE? | No |
| Public stock price? | No |
| Private-market shares? | Yes, subject to eligibility and availability |
| IPO completed? | No |
| Can ordinary brokerage customers buy it? | No |
| Latest reported private valuation | About $15 billion |
| Company type | Private healthcare AI company |
The status above is based on information available through October 2026. Private-company data can change quickly, so investors should verify any future listing announcement through company or regulatory sources.
What Is OpenEvidence?
OpenEvidence is an artificial-intelligence company focused on medical information and clinical decision support.
Its platform allows healthcare professionals to search medical knowledge and receive AI-assisted answers based on medical literature and other clinical sources. The company describes itself as a medical information platform and says its service is available to verified U.S. healthcare professionals. Oopenevidence.com
The company was founded by Daniel Nadler and Zachary Ziegler. Sequoia Capital lists OpenEvidence as a company founded in 2022 and identifies Nadler and Ziegler on its team page. SSequoia Capital
OpenEvidence has attracted investors including Sequoia Capital, Google Ventures, Kleiner Perkins, Thrive Capital and other venture and institutional investors. Its funding history has helped push the company into the group of highly valued private AI companies. Oopenevidence.com+1
Does OpenEvidence Have a Stock Ticker?
No. OpenEvidence does not currently have an official public stock ticker.
A ticker symbol is normally assigned to securities traded on a public exchange. Since OpenEvidence has not completed an IPO or another public listing, investors cannot search for an OpenEvidence ticker in the same way they would search for a listed company such as an established technology or healthcare stock.
This distinction matters because some websites may display an “OpenEvidence stock price” or a symbol-like identifier.
Those figures should not be confused with a public-market quotation.
Nasdaq Private Market specifically states that OpenEvidence has no ticker symbol because it remains a private company. NNasdaq Private Market
Is There an OpenEvidence Stocks Price?
There is no official public stock price for OpenEvidence.
Private companies can have estimated or transaction-based share prices, but these are different from the continuously updated prices of publicly traded stocks.
For example, Nasdaq Private Market has published private-market pricing information for OpenEvidence. Its page showed an estimated price per share of $544.60 as of September 9, 2026. However, this should not be interpreted as an NYSE- or Nasdaq-listed market price. NNasdaq Private Market
Other private-market data providers can report different estimates because private-company transactions are less standardized and much less liquid than public-market trading.
That is why it would be misleading to write that “OpenEvidence stock is trading at $X” without explaining the source and nature of the figure.
Why Private-Market Prices Can Differ
Private-company shares can vary in price because of:
- Different share classes and investor rights
- Limited numbers of buyers and sellers
- Company transfer restrictions
- Secondary-market transaction conditions
- Differences between preferred and common shares
- Investor eligibility requirements
- Limited disclosure compared with public companies
- Different dates for the underlying transactions
Consequently, a private-market share estimate is not equivalent to a live stock-market quote.
What Is OpenEvidence’s Valuation?
OpenEvidence’s private valuation has increased substantially as the company has raised additional capital.
In January 2026, TechCrunch reported that OpenEvidence raised $250 million in Series D financing at a $12 billion valuation. The company had previously been valued at $6 billion in a 2025 financing round. TTechCrunch
More recently, September 2026 reporting indicated that OpenEvidence raised another approximately $250 million and reached a valuation of about $15 billion. Business Insider reported that the September financing involved hospital systems and Andreessen Horowitz. BBusiness Insider
That valuation is important for understanding why interest in OpenEvidence stock has increased. However, a private funding-round valuation is not the same thing as a public stock-market capitalization.
A financing valuation reflects the terms of a particular private transaction. It does not mean investors can immediately purchase OpenEvidence shares at that valuation through a brokerage account.
OpenEvidence Funding and Valuation Timeline
The following timeline provides useful context without treating private valuations as public stock prices.
| Date | Development | Reported Valuation |
|---|---|---|
| February 2025 | Series A financing | About $1 billion |
| July 2025 | Series B financing | About $3.5 billion |
| October 2025 | Additional financing | About $6 billion |
| January 2026 | Series D financing | About $12 billion |
| September 2026 | New funding reported | About $15 billion |
OpenEvidence’s July 2025 financing announcement said the company raised $210 million at a $3.5 billion valuation, with Google Ventures and Kleiner Perkins leading the round. PPR Newswire
The January 2026 financing was reported as a $250 million round at a $12 billion valuation. TTechCrunch
September 2026 reporting subsequently put the company’s valuation at approximately $15 billion following another financing round. BBusiness Insider
Because these are private financings rather than public offerings, investors should not interpret the valuation figures as guaranteed company values or as a prediction of a future IPO price.
Is OpenEvidence Going Public?
There is currently no confirmed OpenEvidence IPO date.
The company has grown rapidly and has raised substantial private capital, factors that can make an eventual public offering possible. However, neither rapid growth nor a high private valuation guarantees that a company will go public.
A company can remain private for many years, raise additional private capital, be acquired, restructure its ownership, or pursue another strategic path.
Therefore, an OpenEvidence IPO should currently be treated as a possibility rather than a confirmed event.
For investors monitoring the situation, the most meaningful signals would include:
- An official OpenEvidence announcement about an IPO
- An SEC registration statement
- A publicly announced exchange listing
- A confirmed underwriting arrangement
- An official prospectus
- A company announcement providing a proposed ticker or listing venue
The SEC’s EDGAR system is one of the primary places investors can monitor regulatory filings when a company begins the formal public-offering process. SSEC
How Can Investors Get Exposure to OpenEvidence?
For most retail investors, there is currently no straightforward way to buy OpenEvidence through a normal brokerage account.
Some private-market platforms facilitate transactions involving shares of private companies. However, eligibility requirements can apply.
Nasdaq Private Market currently states that purchasing OpenEvidence shares through its marketplace requires accredited-entity or institutional-investor status. It also notes that transactions can require company approval. NNasdaq Private Market
Other private secondary marketplaces may have their own requirements and availability.
This means “pre-IPO OpenEvidence stock” should not be interpreted as an ordinary investment product available to everyone.
Investors considering private-company shares should also understand that liquidity can be limited. Even if someone purchases private shares, they may not be able to sell them whenever they want.
What Investors Should Watch Before an OpenEvidence IPO
1. Revenue and business growth
OpenEvidence’s adoption among healthcare professionals is one of the factors attracting attention to the company.
The company said in its 2025 funding announcement that its platform was being used across more than 10,000 hospitals and medical centers and by more than 40% of U.S. physicians who logged in daily. PPR Newswire
Those figures are company-reported metrics rather than audited public-company financial results, so they should be viewed in that context.
2. Healthcare AI competition
OpenEvidence operates in a rapidly developing healthcare-AI market.
Large technology companies and specialized healthcare-AI businesses are also developing tools for physicians and healthcare organizations. Reuters reported in September 2026 that OpenEvidence and Anthropic were collaborating to expand AI-powered clinical decision support into additional countries. RReuters
Competition could affect future growth, pricing, customer acquisition and operating costs.
3. Regulatory and clinical risks
Healthcare AI carries unique risks because inaccurate or poorly contextualized information can have serious consequences.
OpenEvidence is designed to support clinicians rather than replace professional medical judgment, but investors evaluating the company should still pay attention to accuracy, evidence quality, privacy, regulatory issues and liability.
4. Valuation
A rapidly increasing private valuation can be attractive from a growth perspective, but it also creates an important investment question: what expectations are already reflected in that valuation?
A $15 billion private valuation does not automatically mean the company is worth $15 billion in a future public market.
Public investors would eventually need to evaluate revenue, profitability, growth rates, competitive positioning, dilution and other financial metrics.
OpenEvidence Stock vs. a Public Healthcare Stock
It is useful to understand the difference between owning OpenEvidence shares privately and owning a publicly traded healthcare or technology stock.
| Feature | OpenEvidence | Public Company |
|---|---|---|
| Public exchange listing | No | Yes |
| Public ticker | No | Usually yes |
| Live market price | No | Yes |
| SEC public-company reporting | Not equivalent to a listed issuer’s regular reporting | Generally required |
| Retail brokerage access | Generally unavailable | Usually available |
| Liquidity | Limited | Generally much higher |
| Private funding valuations | Yes | Not the primary pricing mechanism |
| IPO completed | No | Yes |
This is why searches for “OpenEvidence stock price” can be confusing. Private-market websites may publish estimates, but those estimates do not turn OpenEvidence into a publicly traded company.
Risks of Buying Private OpenEvidence Shares
Private-market investing can involve risks that are less obvious when compared with ordinary stocks.
Limited liquidity
There may not be a ready buyer when an investor wants to sell.
Valuation uncertainty
Private valuations are generally based on financing rounds and private transactions rather than continuous exchange trading.
Limited financial disclosure
Private companies generally do not provide the same level of standardized financial reporting that investors receive from public companies.
Transfer restrictions
The company may have rights or contractual restrictions affecting whether shares can be transferred.
Dilution
Future financing rounds can change the ownership percentage represented by existing shares.
High expectations
A rapidly increasing valuation can create substantial expectations for future growth. If growth does not match those expectations, a future valuation could be lower.
These risks do not mean OpenEvidence will or will not succeed. They simply illustrate why private-company shares should not be treated as equivalent to ordinary publicly traded stocks.
What Would Need to Happen for OpenEvidence Stocks to Become Public?
If OpenEvidence eventually chooses to pursue an IPO, investors would normally expect a formal public-offering process.
That could involve regulatory filings, financial disclosures, investment banks, an offering prospectus, investor presentations and ultimately an exchange listing.
At that point, the company could receive a public ticker symbol and its shares could begin trading on an exchange.
Until that happens, references to “OpenEvidence stock” should be understood as references to the company’s private shares or to private-market estimates—not a publicly traded security.
Investors can monitor the SEC’s EDGAR database for relevant filings and OpenEvidence’s official announcements for company news. SSEC+1
Frequently Asked Questions
Is OpenEvidence publicly traded?
No. As of October 2026, OpenEvidence remains privately held and is not publicly traded on the NYSE, Nasdaq or another major public stock exchange. NNasdaq Private Market+1
What is the OpenEvidence stock ticker?
OpenEvidence does not currently have a public stock ticker because it has not completed a public listing. NNasdaq Private Market
What is the current OpenEvidence stocks price?
There is no official public-market stock price. Private-market platforms publish transaction data or estimated share values, but these should not be confused with a live exchange price. NNasdaq Private Market
What is OpenEvidence worth?
Recent September 2026 reporting put OpenEvidence’s private valuation at approximately $15 billion following a new financing round. This is a private-company valuation, not a public stock-market capitalization. BBusiness Insider
Can retail investors buy OpenEvidence stocks?
Not through a normal brokerage account or public stock exchange. Some private secondary-market transactions may be available to eligible investors, but requirements, availability and transfer restrictions can apply. Nasdaq Private Market currently identifies accredited entities and institutional investors as eligible buyers on its platform. NNasdaq Private Market
Does OpenEvidence have an IPO date?
No confirmed IPO date has been announced. Investors should not treat speculation about a future IPO as a confirmed event.
How can I track OpenEvidence before an IPO?
Investors can monitor OpenEvidence’s official announcements, reliable financial reporting, private-market information and the SEC’s EDGAR database for any future registration filings. A confirmed IPO would normally involve formal regulatory and company disclosures.
Conclusion
OpenEvidence stock is not publicly traded as of October 2026. The company does not currently have a public ticker, and investors cannot purchase its shares through a normal brokerage account.
Interest in OpenEvidence has nevertheless increased because the healthcare-AI company has attracted major venture investors and achieved rapidly rising private valuations. Recent reporting placed its valuation at approximately $15 billion after a September 2026 funding round. BBusiness Insider
Private-market platforms may provide access to OpenEvidence shares for certain eligible investors, but those transactions are not equivalent to buying a listed stock. Private shares can involve accreditation requirements, limited liquidity, transfer restrictions and valuation uncertainty.
For investors searching for an OpenEvidence IPO, the key distinction is simple: an eventual IPO is possible, but there is currently no confirmed public listing or ticker to buy.
Until OpenEvidence officially files for and completes a public offering, the safest way to describe it is as a private healthcare-AI company—not a publicly traded stock.
